6-K 1 dp50566_6k.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934


For the month of October, 2014
 
 
Commission File Number: 001-13742

ISRAEL CHEMICALS LTD.
(Exact name of registrant as specified in its charter)

Israel Chemicals Ltd.
Millennium Tower
23 Aranha Street
P.O. Box 20245
Tel Aviv, 61202 Israel
(972-3) 684-4400
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F
X
  
Form 40-F
  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes
    
No
X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes
    
No
X
 
 
 
 
 
 


 
ISRAEL CHEMICALS LTD.
 
This report on Form 6-K is being furnished to provide the following information that was filed in Israel by Israel Chemicals Ltd. pursuant to Israeli Securities Law requirements.  This report is being furnished and not filed.

 
1.
Immediate report dated October 29, 2014 regarding the ICL Annual and Extraordinary General Meeting
 
 
 
 
 

 
Item 1
ICL Annual and Extraordinary General Meeting

Further to the immediate reports dated October 7, 2014 (reference number 2014-01-172278 and 2014-01-172311), regarding the postponement of the General Meeting, the Company has established December 11, 2014 as the date for its Annual and Extraordinary General Meeting, and has established November 10, 2014, as the record date to determine who is eligible to vote.

Sincerely,
Israel Chemicals Ltd.


Name of the authorized signatory on the report and the name of the authorized electronic signatory: Lisa Haimovitz
Position: Vice President, General Counsel and Corporate Secretary
Date of Signature: October 29, 2014
 
 
 
 
 
SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

   
Israel Chemicals Ltd.
  
       
       
     
By:
/s/ Avi Doitchman
  
       
Name:
Avi Doitchman
  
       
Title:
Executive Vice President, Chief Financial Officer & Strategy
  
 
 
   
Israel Chemicals Ltd.
  
       
       
     
By:
/s/ Lisa Haimovitz
  
       
Name:
Lisa Haimovitz
  
       
Title:
Vice President, General Counsel and Corporate Secretary
  

Date: October 29, 2014